The Effects of TNF-α Inhibition on the Metabolism of Cartilage: Relationship Between KS, HA, HAPLN1 and ADAMTS4, ADAMTS5, TOS and TGF-β1 Plasma Concentrations in Patients with Juvenile Idiopathic Arthritis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Apr 12

PMID 35407621

Authors

Kornelia Kuznik-Trocha

Katarzyna Winsz-Szczotka

Iwona Lachor-Motyka

Klaudia Dabkowska

Magdalena Wojdas

Krystyna Olczyk

Katarzyna Komosinska-Vassev

Affiliations

Soon will be listed here.

Abstract

Methods: Quantitative evaluation of keratan sulfate (KS), hyaluronic acid (HA), hyaluronan and proteoglycan link protein 1 (HAPLN1), as potential biomarkers of joint dysfunction, and the levels of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) 4 and 5, total oxidative status (TOS) and transforming growth factor (TGF-β1) was performed (using immunoenzymatic methods) in blood obtained from patients before and after 24 months of etanercept (ETA) treatment.

Results: When compared to the controls, KS, HA and HAPLN1 levels were significantly higher in patients with an aggressive course of JIA qualified for ETA treatment. An anti-cytokine therapy leading to clinical improvement promotes the normalization only of the HA level. Proteolytic and pro-oxidative factors, present in high concentrations in patients before the treatment, correlated with HAPLN1, but not with KS and HA levels. In these patients, negative correlations were found between the levels of TGF-β1 and KS, HA and HAPLN1.

Conclusion: The anti-TNF-α therapy used in patients with JIA has a beneficial effect on ECM cartilage metabolism, but it does not completely regenerate it. The changes in the plasma HA level during the anti-cytokine therapy suggest its potential diagnostic utility in monitoring of disease activity and may be used to assess the efficacy of ETA treatment.

Citing Articles

Serum CS/DS, IGF-1, and IGFBP-3 as Biomarkers of Cartilage Remodeling in Juvenile Idiopathic Arthritis: Diagnostic and Therapeutic Implications.

Winsz-Szczotka K, Kuznik-Trocha K, Kozma E, Zeglen B, Gruenpeter A, Wisowski G Biomolecules. 2025; 14(12.

PMID: 39766233 PMC: 11673752. DOI: 10.3390/biom14121526.

Evaluating anticancer activity of emodin by enhancing antioxidant activities and affecting PKC/ADAMTS4 pathway in thioacetamide-induced hepatocellular carcinoma in rats.

Hassan H, Hamdan A, Alattar A, Alshaman R, Bahattab O, Al-Gayyar M Redox Rep. 2024; 29(1):2365590.

PMID: 38861483 PMC: 11168332. DOI: 10.1080/13510002.2024.2365590.

Investigation of Glycosaminoglycans in Urine and Their Alteration in Patients with Juvenile Idiopathic Arthritis.

Lato-Kariakin E, Kuznik-Trocha K, Gruenpeter A, Komosinska-Vassev K, Olczyk K, Winsz-Szczotka K Biomolecules. 2023; 13(12).

PMID: 38136608 PMC: 10742273. DOI: 10.3390/biom13121737.

Proteomic profiling of extracellular vesicles in synovial fluid and plasma from Oligoarticular Juvenile Idiopathic Arthritis patients reveals novel immunopathogenic biomarkers.

Raggi F, Bartolucci M, Cangelosi D, Rossi C, Pelassa S, Trincianti C Front Immunol. 2023; 14:1134747.

PMID: 37205098 PMC: 10186353. DOI: 10.3389/fimmu.2023.1134747.

GAAGs, COMP, and YKL-40 as Potential Markers of Cartilage Turnover in Blood of Children with Juvenile Idiopathic Arthritis Treated with Etanercept-Relationship with ADAMTS4, ADAMTS5, and PDGF-BB.

Dabkowska K, Wojdas M, Kuznik-Trocha K, Wisowski G, Gruenpeter A, Komosinska-Vassev K J Clin Med. 2022; 11(17).

PMID: 36079004 PMC: 9457057. DOI: 10.3390/jcm11175069.

References

Wojdas M, Dabkowska K, Winsz-Szczotka K . Alterations of Extracellular Matrix Components in the Course of Juvenile Idiopathic Arthritis. Metabolites. 2021; 11(3). PMC: 7996267. DOI: 10.3390/metabo11030132. View

Campo G, Avenoso A, Campo S, DAscola A, Nastasi G, Calatroni A . Molecular size hyaluronan differently modulates toll-like receptor-4 in LPS-induced inflammation in mouse chondrocytes. Biochimie. 2009; 92(2):204-15. DOI: 10.1016/j.biochi.2009.10.006. View

Winsz-Szczotka K, Kuznik-Trocha K, Komosinska-Vassev K, Jura-Poltorak A, Olczyk K . Laboratory Indicators of Aggrecan Turnover in Juvenile Idiopathic Arthritis. Dis Markers. 2016; 2016:7157169. PMC: 4748107. DOI: 10.1155/2016/7157169. View

Altinel Acoglu E, Erel O, Yazilitas F, Bulbul M, Oguz M, Yucel H . Changes in thiol/disulfide homeostasis in juvenile idiopathic arthritis. Pediatr Int. 2018; 60(6):593-596. DOI: 10.1111/ped.13569. View

Huang K, Wu L . Aggrecanase and aggrecan degradation in osteoarthritis: a review. J Int Med Res. 2008; 36(6):1149-60. DOI: 10.1177/147323000803600601. View

van der Kraan P . Differential Role of Transforming Growth Factor-beta in an Osteoarthritic or a Healthy Joint. J Bone Metab. 2018; 25(2):65-72. PMC: 5995759. DOI: 10.11005/jbm.2018.25.2.65. View

Dancevic C, McCulloch D . Current and emerging therapeutic strategies for preventing inflammation and aggrecanase-mediated cartilage destruction in arthritis. Arthritis Res Ther. 2015; 16(5):429. PMC: 4289229. DOI: 10.1186/s13075-014-0429-9. View

Shen J, Li S, Chen D . TGF-β signaling and the development of osteoarthritis. Bone Res. 2014; 2. PMC: 4274935. DOI: 10.1038/boneres.2014.2. View

Fosang A, Rogerson F, East C, Stanton H . ADAMTS-5: the story so far. Eur Cell Mater. 2008; 15:11-26. DOI: 10.22203/ecm.v015a02. View

10.

Szeremeta A, Jura-Poltorak A, Zon-Giebel A, Kopec-Medrek M, Kucharz E, Olczyk K . Aggrecan Turnover in Women with Rheumatoid Arthritis Treated with TNF-α Inhibitors. J Clin Med. 2020; 9(5). PMC: 7290997. DOI: 10.3390/jcm9051377. View

11.

Bondeson J, Wainwright S, Hughes C, Caterson B . The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin Exp Rheumatol. 2008; 26(1):139-45. View

12.

Petty R, Southwood T, Manners P, Baum J, Glass D, Goldenberg J . International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004; 31(2):390-2. View

13.

Mort J, Geng Y, Fisher W, Roughley P . Aggrecan heterogeneity in articular cartilage from patients with osteoarthritis. BMC Musculoskelet Disord. 2016; 17:89. PMC: 4758135. DOI: 10.1186/s12891-016-0944-8. View

14.

Wallace C, Giannini E, Huang B, Itert L, Ruperto N . American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011; 63(7):929-36. DOI: 10.1002/acr.20497. View

15.

Rodriguez E, Roughley P . Link protein can retard the degradation of hyaluronan in proteoglycan aggregates. Osteoarthritis Cartilage. 2006; 14(8):823-9. DOI: 10.1016/j.joca.2006.02.008. View

16.

Fuller E, Smith M, Little C, Melrose J . Zonal differences in meniscus matrix turnover and cytokine response. Osteoarthritis Cartilage. 2011; 20(1):49-59. DOI: 10.1016/j.joca.2011.10.002. View

17.

Bondeson J, Blom A, Wainwright S, Hughes C, Caterson B, van den Berg W . The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum. 2010; 62(3):647-57. DOI: 10.1002/art.27290. View

18.

Winsz-Szczotka K, Komosinska-Vassev K, Kuznik-Trocha K, Gruenpeter A, Lachor-Motyka I, Olczyk K . Influence of proteolytic-antiproteolytic enzymes and prooxidative-antioxidative factors on proteoglycan alterations in children with juvenile idiopathic arthritis. Clin Biochem. 2014; 47(9):829-34. DOI: 10.1016/j.clinbiochem.2014.01.027. View

19.

Winsz-Szczotka K, Kuznik-Trocha K, Gruenpeter A, Wojdas M, Dabkowska K, Olczyk K . Association of Circulating COMP and YKL-40 as Markers of Metabolic Changes of Cartilage with Adipocytokines in Juvenile Idiopathic Arthritis. Metabolites. 2020; 10(2). PMC: 7073573. DOI: 10.3390/metabo10020061. View

20.

Roughley P, Mort J . The role of aggrecan in normal and osteoarthritic cartilage. J Exp Orthop. 2016; 1(1):8. PMC: 4648834. DOI: 10.1186/s40634-014-0008-7. View